

# UK Dementias Research Platform

 [consortiapedia.fastercures.org/consortia/uk-dementias-research-platform/](http://consortiapedia.fastercures.org/consortia/uk-dementias-research-platform/)

## Research Areas



### Tool Development

Innovation



### Biomarker Research

Diagnostic



### Basic Research



### Product Development

Drugs

## At a Glance

- Status: **Active Consortium**
- Year Launched: **2014**
- Initiating Organization: **Medical Research Council**
- Initiator Type: **Government**
- Location: **Europe**

## Abstract

The dementias are a progressive, debilitating, and presently incurable set of conditions characterized by neurodegeneration with a severe decline in cognitive functioning, including memory and communication. Around 850,000 people in the UK suffer from dementia with a socioeconomic cost of over £26 billion a year. The MRC Dementias Platform UK (DPUK) was established in 2014. It is a multi-million pound public-private partnership, developed, and led by the MRC, to accelerate progress in and open up dementias research.

## Mission

The aims of DPUK are early detection, improved treatment and ultimately the prevention of dementias. Researchers across the UK now benefit from DPUK's high technology networks for imaging, stem cells and informatics, which link institutions up and down the country with state-of-the-art equipment.

## Consortium History

---

For information of past consortium events, click [here](#)

## Structure & Governance

---

DPUK is governed by:

The MRC Oversight Board which monitors the performance of DPUK and advises on future developments

Scientific Steering Group and Industrial partners, to provide scientific and strategic input to the Executive Team.

Executive Team comprising academic leaders of the consortium and industry representatives to inform the Operations Team.

DPUK is directed by Professor John Gallacher at the University of Oxford, together with an Executive Team of investigators drawn from the Platform's academic and company partners.

## Financing

---

MRC is providing £12m funding for DPUK for an initial period of five years. This core award is supplemented by £4m from six industry partners through a mixture of cash and valuable company resources such as research tools, analytical capabilities, and expertise. These investments have been significantly enhanced by £37m MRC funding for networks of clinical research infrastructure.

## Data Sharing

---

DPUK is being set up for use as a research resource for the scientific community.

The Cohort Directory and Matrix are openly available on the DPUK website. Researchers can register for an account via the website, which will provide access to the DPUK data portal.

## Impact/Accomplishment

---

For news relating to the consortium, click [here](#)

## Links/Social Media Feed

---

Homepage <https://www.dementiasplatform.co.uk/>

## Points of Contact

---

Email: [info@dementiasplatform.uk](mailto:info@dementiasplatform.uk)

Telephone: 08000 232 000

Professor John Gallacher  
Department of Psychiatry  
University of Oxford  
Warneford Hospital  
Warneford Lane  
Oxford OX3 7JX

## Sponsors & Partners

---

Aracolon Biotech

MedImmune, the global biologics research & development arm of AstraZeneca

GlaxoSmithKline

Ixico

Janssen Pharmaceuticals in collaboration with Johnson & Johnson Innovation

SomaLogic

---

Updated: **06/27/2017**